Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reported on a 3-year-old child with vitamin D-dependent rickets type II treated in the Gaza Strip, whose condition deteriorated despite vitamin D and calcium treatments, leading to recurrent chest infections, respiratory failure, and eventual death.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

Mutations in the hHb6 gene cause the hair disorder monilethrix.

This study found that among 17 beta-(N-ureylene-N,N'-disubstituted)-4-azasteroids, those with an N'-phenyl moiety were the most effective inhibitors of human type I 5 alpha-reductase.

This study introduced and evaluated Ahmad's NPRT system for documenting hair loss, finding it helpful in assessing the specific state of male pattern baldness in 500 patients.

This study found that sebaceous glands in bald scalp have greater androgen binding affinity and capacity than those in hairy scalp, possibly contributing to the androgenic response seen in male pattern baldness.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

This meta-analysis suggests that any pattern of male baldness may be associated with a decreased risk of testicular cancer, with stage II hair loss providing the strongest protective effect.

This study found that trans-3,4'-Dimethyl-3-hydroxyflavanone reduces active TGF-beta2 levels in human keratinocytes, suggesting it may enhance hair growth by suppressing the TGF-beta2 activation pathway.

In this study, 1,25-dihydroxyvitamin D3 inhibited growth and promoted differentiation in normal hair follicle cells but did not affect cells from a patient with vitamin D-dependent rickets type II, assisting in potential rapid diagnosis of the condition.

This study found no significant association between the degree of male-pattern baldness and serum 25-hydroxyvitamin D levels in healthy middle-aged and older men.

This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

This study validated the differential stripping technique on hairless rat skin and found that the P-08–016 formulation delivered more finasteride to the epidermis and appendages compared to P-10–008.

This clinical trial found that combining 678 nm helmet-type low-level laser therapy with topical minoxidil 5% significantly increased hair density and patient satisfaction in men with androgenetic alopecia, compared to using minoxidil alone. Both treatments were well tolerated.

This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.

This study found that individuals with early onset extensive androgenetic alopecia have an elevated ratio of DHT to testosterone, but no significant genetic linkage to markers on chromosomes 2 or 5 was detected.

This article provides a detailed review of minoxidil's pharmacological effects for treating androgenic alopecia but reports no new clinical results.

Men with baldness have higher levels of specific proteins, suggesting local hormone production may play a role in hair loss.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

This study found that the prevalence of androgenetic alopecia in Chinese men was lower than in Caucasian men, similar to Korean men, and most commonly presented as type III vertex.

This study found that in vitro treatments with 5alpha-reductase inhibitors and androgen receptor antagonists strongly stimulate VEGF expression in dermal papilla cells.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This article discusses the medical management of male pattern hair loss and reports no new clinical findings.

This study suggests the average age of onset for androgenic alopecia may be decreasing, but a longer-term study is needed to confirm this observation.